-- 獨立研究機構CFRA向提供了以下研究報告。 CFRA分析師總結如下：CAKE公佈的第一季調整後每股收益為1.05美元，年成長13%，高於市場普遍預期的1.01美元；總營收為9.79億美元，年成長5.6%，也高於市場普遍預期的9.65億美元。調整後營業收入為5,700萬美元（年增7%），高於先前預期的5,500萬美元。儘管食品和勞動成本均上漲了5%，但營業利潤率仍維持在5.8%的穩定水準。這是利潤率連續第三個季度保持穩定，顯示管理層透過員工留任和供應鏈措施持續抵銷成本波動，從而有效提升了營運效率。儘管受到天氣因素的影響，但業績仍超出預期。管理層重申了2026年開設至多26家新餐廳的計劃，其中包括至多6家Cheesecake Factory門市以及多家North Italia、Flower Child和FRC品牌門市。該公司保持了 6.016 億美元的強勁流動性，沒有未償債務，並透過 1,920 萬美元的股票回購和每季 0.30 美元的股息返還了資本，這反映出對現金流的信心。
Related Articles
Asia
Electro Optic Systems Reports Contract Backlog Growth as of March 31
Electro Optic Systems Holdings (ASX:EOS) reported a contract backlog of AU$518 million as of March 31, up 13% from the end of 2025, according to a Thursday filing with the Australian bourse.The company closed the March quarter with unrestricted cash holdings of AU$95.1 million, representing a decrease of AU$11.8 million from the end of 2025, per the filing.
$ASX:EOS
Asia
Regis Healthcare Expects Fiscal 2026 Underlying EBITDA at Top End of Guidance
Regis Healthcare (ASX:REG) said it expects fiscal 2026 underlying earnings before interest, taxes, depreciation, and amortization (EBITDA) of about AU$135 million, at the top end of guidance, according to a Thursday Australian bourse filing.Occupancy across mature homes averaged about 96% in the fiscal third quarter, per the filing.The company said it generated net refundable accommodation deposit (RAD) cash inflows of AU$44.5 million in the third quarter, taking the total net RAD cash inflows for the year to date to AU$223 million.As resident turnover occurs, the progressive repricing of existing paid-up RADs to current advertised room prices is expected to generate net operating cash inflows of about AU$400 million over time while also increasing RAD retention earnings, the company added.
$ASX:REG
Research
Research Alert: CFRA Keeps Hold Opinion On Shares Of Mondelez International
CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:Our 12-month target price of $63, raised $1, reflects a 19x multiple of projected 2027 EPS, in line with MDLZ's historical forward P/E average. We raise our 2026 EPS estimate by $0.06 to $3.08, but cut 2027's by $0.11 to $3.32. We continue to see headwinds related to chocolate and biscuits divisions, though favorable forex has been helping to a degree. MDLZ highlighted plans to stimulate growth with more promotional activity, which could boost revenues (we see an acceleration in revenues in 2027), but may come with the trade-off of narrower margins. We note that cost-saving efforts can also contribute to staving off some of the margin pressure. MDLZ is largely hedged on its cocoa input costs for 2026 but less so in 2027. Thus, if the substantial rise in cocoa pricing in 2025 does not reemerge, it should help the bottom line in 2027 as cost pressures should ease. Share buybacks have also contributed to EPS, and we note that Q1 2026 share count was down 1.5% from one year earlier.
$MDLZ